Subsidiary’s Drug Production License Changed
January 22, 2026
Source: drugdu
26
On January 21, Buchang Pharma's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., has obtained a renewed Drug Production License from the Shandong Provincial Drug Administration, which has approved the application for changes to the license. The issuing authority is the Shandong Provincial Drug Administration. Details of the changes: Contract manufacturing has been approved, with Yangling Buchang Pharmaceutical Co. , Ltd. and Shandong Buchang Pharmaceutical Co., Ltd. as the contract manufacturers. The products to be manufactured are loxoprofen sodium oral solution (10ml: 60mg) and melogabalin besylate tablets (2.5mg (C12H19NO2) - 5mg (C12H19NO2)). The contract manufacturing validity period is until July 16, 2028, and is limited to product registration applications. Approval information has also been added, involving ibuprofen sustained-release capsules (National Drug Approval Number H20255656). This change will help the company optimize its production structure, maintain stable production capacity, meet market demand, and have a positive impact on the company's future operations. License Number: Lu 20160251.
https://finance.eastmoney.com/a/202601213626159422.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Recombinant Zoster Vaccine (Shingles Vaccine) Receives Clinical Trial Approval Notice January 22, 2026
- HeartCare Medical (06609.HK) Announces NMPA Acceptance of Registration Application for Self-Expanding Intracranial Drug-Eluting Stent January 22, 2026
- Two drugs from Hengrui Medicine have received clinical trial approval January 22, 2026
- Sunshine Novo’s Small Nucleic Acid Drug IND Application Accepted; Innovative Drug Pipeline Enters Harvest Phase January 22, 2026
- Big news! Chia Tai Tianqing’s oral GLP-1 has been approved for clinical trials! Can its differentiated “biased” mechanism break through the red ocean market? January 22, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
